Perspective Therapeutics falls after update on Phase 1/2a trial

Shares of Perspective Therapeutics (CATX) are down $1.52, or 34%, to $2.97 after the radiopharmaceutical company announced that updated interim results from its ongoing Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors were presented at the European Society for Medical Oncology Congress 2025 taking place October 17-21 in Berlin, Germany. Interim results with a data cut-off date of September 12, 2025 formed the basis of the ESMO presentation. In this analysis, 55 patients across three dose cohorts received at least one treatment of VMT-alpha-NET. Two patients in Cohort 1 and 23 patients in Cohort 2 were with at least 9 months of follow-up since their initial treatment. Results with a data cut-off date of April 30, 2025 were previously presented at the 2025 American Society of Clinical Oncology Annual Meeting in May 2025. At ASCO, the company reported data on 42 patients across two dose cohorts who had received at least one treatment of VMT-alpha-NET and interim efficacy data for two patients in Cohort 1 and seven patients in Cohort 2. As of the September 12, 2025 data cut-off date: 20 out of the 25 patients, or 80%, in Cohorts 1 and 2 were without progression. Eight patients were observed to have response according to investigator assessed RECIST v1.1, all of which were confirmed and occurred in Cohort 2. While all 23 Cohort 2 patients had at least one tumor expressing SSTR2, 16 patients in Cohort 2 had SSTR2 expression in all of their tumors. Among the 16 patients with SSTR2 expression in all tumors, seven experienced confirmed response, or 44%. 14 out of the 16 patients with SSTR2 expression in all tumors were free from disease progression and remained on study, or 87.5%, with median follow-up of 41 weeks. Initial anti-tumor activity observations for an additional 23 patients in Cohort 2 and eight patients in Cohort 3 are pending presentation at a future medical conference in 2026.